The efficacy of curcumin-piperine co-supplementation on clinical symptoms, duration, severity, and inflammatory factors in COVID-19 outpatients: a randomized double-blind, placebo-controlled trial
Abstract Background COVID-19 pandemic has made the disease a major global problem by creating a significant burden on health, economic, and social status. To date, there are no effective and approved medications for this disease. Curcumin as an anti-inflammatory agent can have a positive effect on t...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-06-01
|
| Series: | Trials |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13063-022-06375-w |
| _version_ | 1818253112652070912 |
|---|---|
| author | Gholamreza Askari Amirhossein Sahebkar Davood Soleimani Atena Mahdavi Sahar Rafiee Muhammed Majeed Farzin Khorvash Bijan Iraj Mahshid Elyasi Mohammad Hossein Rouhani Mohammad Bagherniya |
| author_facet | Gholamreza Askari Amirhossein Sahebkar Davood Soleimani Atena Mahdavi Sahar Rafiee Muhammed Majeed Farzin Khorvash Bijan Iraj Mahshid Elyasi Mohammad Hossein Rouhani Mohammad Bagherniya |
| author_sort | Gholamreza Askari |
| collection | DOAJ |
| description | Abstract Background COVID-19 pandemic has made the disease a major global problem by creating a significant burden on health, economic, and social status. To date, there are no effective and approved medications for this disease. Curcumin as an anti-inflammatory agent can have a positive effect on the control of COVID-19 complications. This study aimed to assess the efficacy of curcumin-piperine supplementation on clinical symptoms, duration, severity, and inflammatory factors in patients with COVID-19. Methods Forty-six outpatients with COVID-19 disease were randomly allocated to receive two capsules of curcumin-piperine; each capsule contained 500 mg curcumin plus 5 mg piperine or placebo for 14 days. Results Mean changes in complete blood count, liver enzymes, blood glucose levels, lipid parameters, kidney function, and c-reactive protein (CRP) were not significantly different between the two groups. There was a significant improvement in health status, including dry cough, sputum cough, ague, sore throat, weakness, muscular pain, headache, and dyspnea at week 2 in both curcumin-piperine and placebo groups (P value < 0.05); however, the improvement in weakness was more in the curcumin-piperine group than with placebo group (P value 025). Conclusion The present study results showed that curcumin-piperine co-supplementation in outpatients with COVID-19 could significantly reduce weakness. However, in this study, curcumin-piperine co-supplementation could not significantly affect the other indices, including biochemical and clinical indices. Trial registration Iranian Registry of Clinical Trials IRCT20121216011763N46 . 2020-10-31 |
| first_indexed | 2024-12-12T16:34:54Z |
| format | Article |
| id | doaj.art-96eff8da72d74f8193f668cd85797553 |
| institution | Directory Open Access Journal |
| issn | 1745-6215 |
| language | English |
| last_indexed | 2024-12-12T16:34:54Z |
| publishDate | 2022-06-01 |
| publisher | BMC |
| record_format | Article |
| series | Trials |
| spelling | doaj.art-96eff8da72d74f8193f668cd857975532022-12-22T00:18:42ZengBMCTrials1745-62152022-06-0123111010.1186/s13063-022-06375-wThe efficacy of curcumin-piperine co-supplementation on clinical symptoms, duration, severity, and inflammatory factors in COVID-19 outpatients: a randomized double-blind, placebo-controlled trialGholamreza Askari0Amirhossein Sahebkar1Davood Soleimani2Atena Mahdavi3Sahar Rafiee4Muhammed Majeed5Farzin Khorvash6Bijan Iraj7Mahshid Elyasi8Mohammad Hossein Rouhani9Mohammad Bagherniya10Food Security Research Center, Isfahan University of Medical SciencesApplied Biomedical Research Center, Mashhad University of Medical SciencesResearch Center of Oils and Fats, Kermanshah University of Medical SciencesDepartment of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical SciencesDepartment of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical SciencesSabinsa CorporationNosocomial Infection Research Center, Isfahan University of Medical SciencesIsfahan Endocrine and Metabolism Research Center, Isfahan University of Medical SciencesDepartment of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical SciencesFood Security Research Center, Isfahan University of Medical SciencesFood Security Research Center, Isfahan University of Medical SciencesAbstract Background COVID-19 pandemic has made the disease a major global problem by creating a significant burden on health, economic, and social status. To date, there are no effective and approved medications for this disease. Curcumin as an anti-inflammatory agent can have a positive effect on the control of COVID-19 complications. This study aimed to assess the efficacy of curcumin-piperine supplementation on clinical symptoms, duration, severity, and inflammatory factors in patients with COVID-19. Methods Forty-six outpatients with COVID-19 disease were randomly allocated to receive two capsules of curcumin-piperine; each capsule contained 500 mg curcumin plus 5 mg piperine or placebo for 14 days. Results Mean changes in complete blood count, liver enzymes, blood glucose levels, lipid parameters, kidney function, and c-reactive protein (CRP) were not significantly different between the two groups. There was a significant improvement in health status, including dry cough, sputum cough, ague, sore throat, weakness, muscular pain, headache, and dyspnea at week 2 in both curcumin-piperine and placebo groups (P value < 0.05); however, the improvement in weakness was more in the curcumin-piperine group than with placebo group (P value 025). Conclusion The present study results showed that curcumin-piperine co-supplementation in outpatients with COVID-19 could significantly reduce weakness. However, in this study, curcumin-piperine co-supplementation could not significantly affect the other indices, including biochemical and clinical indices. Trial registration Iranian Registry of Clinical Trials IRCT20121216011763N46 . 2020-10-31https://doi.org/10.1186/s13063-022-06375-wCOVID-19CurcuminPiperineClinical trialClinical symptoms |
| spellingShingle | Gholamreza Askari Amirhossein Sahebkar Davood Soleimani Atena Mahdavi Sahar Rafiee Muhammed Majeed Farzin Khorvash Bijan Iraj Mahshid Elyasi Mohammad Hossein Rouhani Mohammad Bagherniya The efficacy of curcumin-piperine co-supplementation on clinical symptoms, duration, severity, and inflammatory factors in COVID-19 outpatients: a randomized double-blind, placebo-controlled trial Trials COVID-19 Curcumin Piperine Clinical trial Clinical symptoms |
| title | The efficacy of curcumin-piperine co-supplementation on clinical symptoms, duration, severity, and inflammatory factors in COVID-19 outpatients: a randomized double-blind, placebo-controlled trial |
| title_full | The efficacy of curcumin-piperine co-supplementation on clinical symptoms, duration, severity, and inflammatory factors in COVID-19 outpatients: a randomized double-blind, placebo-controlled trial |
| title_fullStr | The efficacy of curcumin-piperine co-supplementation on clinical symptoms, duration, severity, and inflammatory factors in COVID-19 outpatients: a randomized double-blind, placebo-controlled trial |
| title_full_unstemmed | The efficacy of curcumin-piperine co-supplementation on clinical symptoms, duration, severity, and inflammatory factors in COVID-19 outpatients: a randomized double-blind, placebo-controlled trial |
| title_short | The efficacy of curcumin-piperine co-supplementation on clinical symptoms, duration, severity, and inflammatory factors in COVID-19 outpatients: a randomized double-blind, placebo-controlled trial |
| title_sort | efficacy of curcumin piperine co supplementation on clinical symptoms duration severity and inflammatory factors in covid 19 outpatients a randomized double blind placebo controlled trial |
| topic | COVID-19 Curcumin Piperine Clinical trial Clinical symptoms |
| url | https://doi.org/10.1186/s13063-022-06375-w |
| work_keys_str_mv | AT gholamrezaaskari theefficacyofcurcuminpiperinecosupplementationonclinicalsymptomsdurationseverityandinflammatoryfactorsincovid19outpatientsarandomizeddoubleblindplacebocontrolledtrial AT amirhosseinsahebkar theefficacyofcurcuminpiperinecosupplementationonclinicalsymptomsdurationseverityandinflammatoryfactorsincovid19outpatientsarandomizeddoubleblindplacebocontrolledtrial AT davoodsoleimani theefficacyofcurcuminpiperinecosupplementationonclinicalsymptomsdurationseverityandinflammatoryfactorsincovid19outpatientsarandomizeddoubleblindplacebocontrolledtrial AT atenamahdavi theefficacyofcurcuminpiperinecosupplementationonclinicalsymptomsdurationseverityandinflammatoryfactorsincovid19outpatientsarandomizeddoubleblindplacebocontrolledtrial AT saharrafiee theefficacyofcurcuminpiperinecosupplementationonclinicalsymptomsdurationseverityandinflammatoryfactorsincovid19outpatientsarandomizeddoubleblindplacebocontrolledtrial AT muhammedmajeed theefficacyofcurcuminpiperinecosupplementationonclinicalsymptomsdurationseverityandinflammatoryfactorsincovid19outpatientsarandomizeddoubleblindplacebocontrolledtrial AT farzinkhorvash theefficacyofcurcuminpiperinecosupplementationonclinicalsymptomsdurationseverityandinflammatoryfactorsincovid19outpatientsarandomizeddoubleblindplacebocontrolledtrial AT bijaniraj theefficacyofcurcuminpiperinecosupplementationonclinicalsymptomsdurationseverityandinflammatoryfactorsincovid19outpatientsarandomizeddoubleblindplacebocontrolledtrial AT mahshidelyasi theefficacyofcurcuminpiperinecosupplementationonclinicalsymptomsdurationseverityandinflammatoryfactorsincovid19outpatientsarandomizeddoubleblindplacebocontrolledtrial AT mohammadhosseinrouhani theefficacyofcurcuminpiperinecosupplementationonclinicalsymptomsdurationseverityandinflammatoryfactorsincovid19outpatientsarandomizeddoubleblindplacebocontrolledtrial AT mohammadbagherniya theefficacyofcurcuminpiperinecosupplementationonclinicalsymptomsdurationseverityandinflammatoryfactorsincovid19outpatientsarandomizeddoubleblindplacebocontrolledtrial AT gholamrezaaskari efficacyofcurcuminpiperinecosupplementationonclinicalsymptomsdurationseverityandinflammatoryfactorsincovid19outpatientsarandomizeddoubleblindplacebocontrolledtrial AT amirhosseinsahebkar efficacyofcurcuminpiperinecosupplementationonclinicalsymptomsdurationseverityandinflammatoryfactorsincovid19outpatientsarandomizeddoubleblindplacebocontrolledtrial AT davoodsoleimani efficacyofcurcuminpiperinecosupplementationonclinicalsymptomsdurationseverityandinflammatoryfactorsincovid19outpatientsarandomizeddoubleblindplacebocontrolledtrial AT atenamahdavi efficacyofcurcuminpiperinecosupplementationonclinicalsymptomsdurationseverityandinflammatoryfactorsincovid19outpatientsarandomizeddoubleblindplacebocontrolledtrial AT saharrafiee efficacyofcurcuminpiperinecosupplementationonclinicalsymptomsdurationseverityandinflammatoryfactorsincovid19outpatientsarandomizeddoubleblindplacebocontrolledtrial AT muhammedmajeed efficacyofcurcuminpiperinecosupplementationonclinicalsymptomsdurationseverityandinflammatoryfactorsincovid19outpatientsarandomizeddoubleblindplacebocontrolledtrial AT farzinkhorvash efficacyofcurcuminpiperinecosupplementationonclinicalsymptomsdurationseverityandinflammatoryfactorsincovid19outpatientsarandomizeddoubleblindplacebocontrolledtrial AT bijaniraj efficacyofcurcuminpiperinecosupplementationonclinicalsymptomsdurationseverityandinflammatoryfactorsincovid19outpatientsarandomizeddoubleblindplacebocontrolledtrial AT mahshidelyasi efficacyofcurcuminpiperinecosupplementationonclinicalsymptomsdurationseverityandinflammatoryfactorsincovid19outpatientsarandomizeddoubleblindplacebocontrolledtrial AT mohammadhosseinrouhani efficacyofcurcuminpiperinecosupplementationonclinicalsymptomsdurationseverityandinflammatoryfactorsincovid19outpatientsarandomizeddoubleblindplacebocontrolledtrial AT mohammadbagherniya efficacyofcurcuminpiperinecosupplementationonclinicalsymptomsdurationseverityandinflammatoryfactorsincovid19outpatientsarandomizeddoubleblindplacebocontrolledtrial |